September 26, 2019
Shionogi to Present New Data at IDWeek 2019
– Including Cefiderocol Phase III APEKS-NP Trial as Late-breaker Oral Presentation – OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi &…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
September 26, 2019
cTAP’s insights to assist the design and analysis of clinical trials in patients with DMD
cTAP has published a comprehensive analysis of the North Star Ambulatory Assessment (NSAA), a newly adopted primary outcome measure in clinical trials of patients with Duchenne Muscular Dystrophy.
September 26, 2019
Takeda presents efficacy for nacrolepsy type 1 Orexin receptor agonist TAK-925
Takeda’s presentation has shown TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo.
September 26, 2019
Ipsen Showcases Studies at the ESMO 2019 Congress Highlighting Progress in New Approaches for Difficult-to-Treat Cancers
Ipsen’s presentations demonstrate promising advances for the treatment of advanced hepatocellular carcinoma, metastatic pancreatic cancer and neuroendocrine tumors.
September 25, 2019
Entyvio shows superiority over Humira in first head-to-head biologic study in ulcerative colitis
Takeda announced further results from the Varsity study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis
September 25, 2019
Puma Biotechnology to Present at Cantor Global Healthcare Conference
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President…
September 25, 2019
Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
– Presentation to be webcast on www.exelixis.com – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis…
September 25, 2019
Dicerna™ to Present at Two Upcoming Investor Conferences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)…
September 25, 2019
Revance to Participate in the 2019 Cantor Global Healthcare Conference
NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications,…
September 25, 2019
FDA grants approval for Bavarian Nordic’s monkeypox vaccine
The FDA granted the approval of Jynneos for the prevention of monkeypox disease, to Bavarian Nordic A/S, and it granted the application Priority Review, it said Tuesday in a press release.